EA200801081A1 - Способы лечения расстройств центральной нервной системы комбинацией малых доз эсциталопрама и бупропиона - Google Patents

Способы лечения расстройств центральной нервной системы комбинацией малых доз эсциталопрама и бупропиона

Info

Publication number
EA200801081A1
EA200801081A1 EA200801081A EA200801081A EA200801081A1 EA 200801081 A1 EA200801081 A1 EA 200801081A1 EA 200801081 A EA200801081 A EA 200801081A EA 200801081 A EA200801081 A EA 200801081A EA 200801081 A1 EA200801081 A1 EA 200801081A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disorder
escitalopram
bupropion
combination
nervous system
Prior art date
Application number
EA200801081A
Other languages
English (en)
Inventor
Джеффри Джонас
Анджана Боус
Джойс Цай
Original Assignee
Х. Лундбекк А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Х. Лундбекк А/С filed Critical Х. Лундбекк А/С
Publication of EA200801081A1 publication Critical patent/EA200801081A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Настоящее изобретение относится к способу лечения расстройства центральной нервной системы, такого как расстройство настроения (например, большое депрессивное расстройство) или тревожное расстройство (например, генерализованное тревожное расстройство, социофобия, посттравматический стресс и паническое расстройство), комбинацией малых доз эсциталопрама и бупропиона.
EA200801081A 2005-10-14 2006-10-16 Способы лечения расстройств центральной нервной системы комбинацией малых доз эсциталопрама и бупропиона EA200801081A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US72727605P 2005-10-14 2005-10-14
US81088206P 2006-06-02 2006-06-02
US80408606P 2006-06-06 2006-06-06
PCT/US2006/060006 WO2007053796A2 (en) 2005-10-14 2006-10-16 Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion

Publications (1)

Publication Number Publication Date
EA200801081A1 true EA200801081A1 (ru) 2008-10-30

Family

ID=38006532

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200801081A EA200801081A1 (ru) 2005-10-14 2006-10-16 Способы лечения расстройств центральной нервной системы комбинацией малых доз эсциталопрама и бупропиона

Country Status (11)

Country Link
US (2) US7569605B2 (ru)
EP (1) EP1954257A4 (ru)
JP (1) JP2009511606A (ru)
KR (1) KR20080080094A (ru)
AU (1) AU2006308635A1 (ru)
BR (1) BRPI0617382A2 (ru)
CA (1) CA2625835A1 (ru)
EA (1) EA200801081A1 (ru)
IL (1) IL190831A0 (ru)
NO (1) NO20082203L (ru)
WO (1) WO2007053796A2 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7671094B2 (en) 2005-06-27 2010-03-02 Biovail Laboratories International S.R.L. Bupropion hydrobromide and therapeutic applications
EP1896002A4 (en) 2005-06-27 2009-11-25 Biovail Lab Int Srl BUPROPIONAL SALT FORMULATIONS WITH MODIFIED RELEASE
TW200812993A (en) * 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
WO2009035473A2 (en) * 2007-09-13 2009-03-19 Sanfilippo Louis C Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders
US20090246276A1 (en) * 2008-01-28 2009-10-01 Graham Jackson Pharmaceutical Compositions
WO2010136803A1 (en) * 2009-05-26 2010-12-02 Shire Llc Methods of enhancing selective serotonin reuptake inhibitor effects in mammals
WO2012028834A1 (en) * 2010-09-01 2012-03-08 Marcel Petrus Maria Bartels Use of bupropion in treating sexual dysfunction
US20140335139A1 (en) 2013-05-13 2014-11-13 NeuOra Microceuticals, LLC Long lasting breath mint
KR20230136599A (ko) * 2021-01-28 2023-09-26 세이지 테라퓨틱스, 인크. 성 기능장애의 치료를 위한 신경활성 스테로이드의용도

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759838A (fr) * 1969-12-04 1971-06-03 Wellcome Found Cetones a activite biologique
US3885046A (en) * 1969-12-04 1975-05-20 Burroughs Wellcome Co Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression
USRE33994E (en) * 1983-08-16 1992-07-14 Burroughs Wellcome Co. Pharmaceutical delivery system
US4507323A (en) * 1984-07-25 1985-03-26 Burroughs Wellcome Co. Treatment of psychosexual dysfunctions
US4723958A (en) * 1986-05-23 1988-02-09 Merck & Co., Inc. Pulsatile drug delivery system
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5582837A (en) * 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
GB9217295D0 (en) * 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
GB9315856D0 (en) * 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) * 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) * 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
MY113429A (en) 1995-02-28 2002-02-28 Univ Temple Controlled release tablet containing swellable polyethylene oxide
US5656294A (en) * 1995-06-07 1997-08-12 Cibus Pharmaceutical, Inc. Colonic delivery of drugs
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
JP4083818B2 (ja) 1997-06-06 2008-04-30 ディポメド，インコーポレイティド 高度可溶性薬物の制御された放出のための胃滞留性の経口薬物投与形
CA2318920A1 (en) * 1998-01-29 1999-08-05 James W. Young Pharmaceutical uses of optically pure (-)-bupropion
US6372254B1 (en) * 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
US6096341A (en) 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
PL205109B1 (pl) * 1998-11-02 2010-03-31 Elan Pharma Int Ltd Wielocząstkowa kompozycja metylofenidatu o modyfikowanym uwalnianiu i jej zastosowanie
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US6342496B1 (en) * 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
WO2000059481A1 (en) * 1999-04-06 2000-10-12 Pharmaquest Ltd. PHARMACEUTICAL DOSAGE FORM FOR PULSATILE DELIVERY OF d-threo-METHYLPHENIDATE AND A SECOND CNS STIMULANT
AR021155A1 (es) 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
AU7405000A (en) 1999-09-28 2001-04-30 H. Lundbeck A/S Melt granulated composition and modified release dosage form prepared from said composition
DE69920526T2 (de) * 1999-10-25 2006-02-23 H. Lundbeck A/S Verfahren zur herstellung von citalopram
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
AU8395501A (en) * 2000-07-31 2002-02-13 Hoffmann La Roche Piperazine derivatives
US6500457B1 (en) * 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
EA200301195A1 (ru) 2001-05-01 2004-04-29 Х. Лундбекк А/С Применение энантиомерно чистого эсциталопрама
AR034612A1 (es) 2001-06-25 2004-03-03 Lundbeck & Co As H Proceso para la preparacion del citalopram racemico y/o del s- o r-citalopram mediante la separacion de una mezcla de r- y s-citalopram
AR034759A1 (es) 2001-07-13 2004-03-17 Lundbeck & Co As H Metodo para la preparacion de escitalopram
EA006213B1 (ru) 2001-07-31 2005-10-27 Х. Лундбекк А/С Кристаллическая композиция, содержащая эсциталопрам
US20030124196A1 (en) * 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
US7163696B2 (en) * 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
IS7239A (is) 2001-12-14 2004-04-29 H. Lundbeck A/S Aðferð til framleiðslu á essítalóprami
WO2004000280A1 (en) * 2002-04-29 2003-12-31 Shire Laboraties, Inc. Pharmaceutical formulations with improved bioavailability
PT1578738E (pt) * 2002-12-23 2008-04-11 Lundbeck & Co As H Bromidrato de escitalopram e um método para a sua preparação
ATE433328T1 (de) 2002-12-24 2009-06-15 Immunofrontier Inc Polynukleotidhaltige impfstoffe
EP1611118A2 (en) 2003-03-21 2006-01-04 H. Lundbeck A/S Intermediates for the preparation of citalopram and escitalopram
US20050054688A1 (en) * 2003-08-08 2005-03-10 Pfizer Inc Selective serotonin reuptake inhibitors in the treatment of disease
US20050196453A1 (en) * 2004-03-05 2005-09-08 H. Lundbeck A/S Crystalline composition containing escitalopram
AU2005271574A1 (en) * 2004-08-03 2006-02-16 Orexigen Therapeutics, Inc. Combination of bupropion and a second compound for affecting weight loss

Also Published As

Publication number Publication date
CA2625835A1 (en) 2007-05-10
US7569605B2 (en) 2009-08-04
EP1954257A2 (en) 2008-08-13
NO20082203L (no) 2008-07-09
EP1954257A4 (en) 2009-05-20
AU2006308635A1 (en) 2007-05-10
WO2007053796A2 (en) 2007-05-10
IL190831A0 (en) 2008-12-29
JP2009511606A (ja) 2009-03-19
US20070203231A1 (en) 2007-08-30
US20090264522A1 (en) 2009-10-22
BRPI0617382A2 (pt) 2017-07-11
WO2007053796A3 (en) 2007-11-29
KR20080080094A (ko) 2008-09-02

Similar Documents

Publication Publication Date Title
EA200801081A1 (ru) Способы лечения расстройств центральной нервной системы комбинацией малых доз эсциталопрама и бупропиона
NO20055907L (no) Fremgangsmate for behandling av en angstforstyrrelse
DK2018380T3 (da) CNS-aktiverede kondenserede bi-heterocyklisk-substituerede azabicykliske alkanderivater
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
DK1780269T3 (da) Virusrensningsmetoder
BR122012023120B8 (pt) Composto inibidor da recaptação de serotonina
ATE458491T1 (de) Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin
EA201000673A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИЗМЕРЕНИЯ АКТИВАЦИИ Wnt И ДЛЯ ЛЕЧЕНИЯ Wnt-ОПОСРЕДОВАННЫХ РАКОВЫХ ЗАБОЛЕВАНИЙ
BRPI0512856A (pt) métodos e reagentes para o tratamento de distúrbios metabólicos
NO20055208L (no) 4-(2-fenylsulfanyl-fenyl)-piperidinderivater som serotonin-reopptaksinhibitorer
NO20076344L (no) Piperazin-piperidin-antagonister og agonister av 5-HT1A-reseptoren
MX2010005047A (es) Inhibidores de aldh-2 en el tratamiento de enfermedades psiquiatricas.
DE602006004186D1 (de) VERFAHREN ZUR HERSTELLUNG EINER NICHTAROMATISCHEN L-AMINOSÄURE UNTER VERWENDUNG EINES BAKTERIUMS DERRESSION DES csrA-GENS
DK1641456T3 (da) Gaboxadol til behandling af depression og andre affektive lidelser
ATE446299T1 (de) Verfahren zur herstellung von 7-ethyl-10- hydroxycamptothecin
EA200870052A1 (ru) Фармацевтические препаративные формы эсциталопрама модифицированного и пульсирующего высвобождения
DE60201829D1 (de) Azaheterocyclylmethyl derivative des 2,3-dihydro-1,4-dioxino(2,3-f)quinolins als antidepressiva
BRPI0607720A2 (pt) processo aperfeiçoado para a preparação de diidrobenzofuranos substituìdos por (propenil dissubstituìdos) fenilalquila
BR0209343A (pt) Antidepressivos de azaheterociclilmetila derivados de [1,4]-benzodioxanos oxaheterociclo-fundidos; métodos de tratamento usando tais compostos; processo para prepará-los
EA200801080A1 (ru) Стабильные фармацевтические лекарственные формы, содержащие эсциталопрам и бупропион
CR8313A (es) Derivados de arilo cicloalcanol sustituidos y metodos de uso de los mismos
IS7021A (is) Nýjar heteróarýlafleiður, framleiðsla þeirra og notkun
BR0209342A (pt) Antidepressivos de azaheterociclilmetila derivados de 2,3 dihidro-1,4-dioxino[2,3-f]quinoxalina; método de tratamento usando tais compostos; processo para prepará-los
DE602006004893D1 (de) VERFAHREN ZUR HERSTELLUNG EINER L-AMINOSÄURE UNTER VERWENDUNG EINES BAKTERIUMS DER FAMILIE ENTEROBACTERIACEAE MIT ABGESCHWÄCHTER EXPRESSION DES ybiV-GENS
DE60315843D1 (de) Antidepressive indolalkylderivate von heterozyklisch-kondensierten benzodioxanmethylaminen